Moderna Inc. ($MRNA) Stock Forecast: Up 12.6% Today

What is Moderna Inc.?

A biotechnology company with a focus on mRNA technology, Moderna (MRNA), saw its stock make significant gains today.

Why is Moderna Inc. going up?

MRNA stock is up 12.6% on Jun 29, 2026 19:56

• Moderna's stock surged almost 13% to hit a 52-week high as the company revealed its strategies to expand beyond vaccines and venture into broader biotechnology avenues. This move, which includes utilizing its mRNA platform for diverse therapies and incorporating AI for drug discovery, excited investors and led to a rise in the stock price.
• Anticipation surrounding the FDA's upcoming decision regarding Moderna's mRNA flu shot further fueled positive market sentiment. Analysts hurried to revise their price targets as the stock exceeded many of their previous estimates.
• Patton Fund Management Inc. notably increased its position in Moderna, Inc., indicating a growing faith in the company's future prospects and contributing to the stock's bullish trend.
• Market reactions indicate optimism towards Moderna's growth initiatives and the potential applications of its mRNA technology across various therapeutic fields, demonstrating investor trust in the company's long-term trajectory.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines

Moderna's stock (MRNA) rose nearly 13% after the company announced a long-term strategy to diversify beyond vaccines into a broader biotechnology company. The plan involves leveraging its mRNA platform across three "horizons," including commercial products, early-stage clinical programs, and future modalities like in vivo CAR-T therapies. Investors reacted positively to this diversification and the company's intent to use AI to accelerate drug discovery, pushing the stock to a 52-week high.

https://www.tradingview.com/news/zacks:41f1b4918094b:0-mrna-stock-jumps-to-52-week-high-on-expansion-plans-beyond-vaccines/

NovaBridge Biosciences (NBP) Appoints Srishti Gupta as New CEO

NovaBridge Biosciences (NBP) has appointed Srishti Gupta as its new CEO and board member, effective July 1, 2026. Gupta's appointment is expected to drive the company's strategic objectives, particularly in advancing its oncology pipeline with givastomig and exploring new partnerships. Despite a post-announcement stock rise, the company faces challenges with a low GF Score™ and negative earnings, though it maintains strong financial strength.

https://www.gurufocus.com/news/8936046/novabridge-biosciences-nbp-appoints-srishti-gupta-as-new-ceo

HCA Healthcare Announces New England Journal of Medicine Study Highlighting Advances in CRISPR-based Therapy for Children

HCA Healthcare announced that new research published in The New England Journal of Medicine (NEJM) highlights promising results from a gene-editing therapy for children aged 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. The study, led by Dr. Haydar Frangoul of HCA Healthcare's TriStar Centennial Children's Hospital, evaluated the CRISPR-based therapy exagamglogene autotemcel (exa-cel) and demonstrated significant success in achieving transfusion independence for beta thalassemia patients and freedom from severe vaso-occlusive crises for sickle cell disease patients. HCA Healthcare's Sarah Cannon Transplant and Cellular Therapy Network is expanding access to these FDA-approved gene-editing therapies.

https://sg.finance.yahoo.com/news/hca-healthcare-announces-england-journal-123000749.html

Moderna (NASDAQ:MRNA) surge puts stock above most analyst targets ahead of FDA review

Moderna's stock surged over 12% on Friday, closing at $67.27, which is now above most analyst 12-month price targets of $45.42. This surge comes ahead of an Aug. 5 FDA decision on Moderna’s mRNA flu shot, with the company aiming to broaden its perception beyond just a vaccine stock. Analysts are slow to update their targets, and the stock's valuation is being tested by this rapid increase and upcoming regulatory events.

https://ts2.tech/en/moderna-nasdaqmrna-surge-puts-stock-above-most-analyst-targets-ahead-of-fda-review/

Patton Fund Management Inc. Has $4.49 Million Stake in Moderna, Inc. $MRNA

Patton Fund Management Inc. significantly increased its stake in Moderna, Inc. by 1,080.4% in the first quarter, now holding 88,410 shares valued at approximately $4.49 million. Despite this, analysts maintain a "Reduce" consensus rating with an average target price of $37.13 for Moderna. Recent positive news, including Moderna's expanded pipeline in oncology and autoimmune disease, and FDA support for its mRNA flu vaccine, may be leading to a re-evaluation of the stock by investors.

https://www.marketbeat.com/instant-alerts/filing-patton-fund-management-inc-has-449-million-stake-in-moderna-inc-mrna-2026-06-29/

Trending Today

Moderna Inc. ($MRNA) Stock Forecast: Up 12.6% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Down 5.7% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 10.0% Today

Uber Technologies Inc. ($UBER) Stock Forecast: Up 5.3% Today

Eli Lilly and Company ($LLY) Stock Forecast: Up 5.5% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.2% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 5.2% Today

Caterpillar Inc. ($CAT) Stock Forecast: Down 5.6% Today

Unity Software ($U) Stock Forecast: Up 5.3% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.5% Today

Moderna Inc. Price History

17.05.2026 - MRNA Stock was up 10.8%

• Moderna's bullish movement today could be attributed to the anticipation and positive sentiment surrounding its upcoming Investor Event Science Day, where the company will showcase its research and development programs, emphasizing the potential of its mRNA platform in new therapeutic areas.
• The alignment with the FDA for its mRNA flu vaccine and the upcoming advisory committee meeting might have also contributed to investor optimism, reflecting confidence in Moderna's pipeline and regulatory progress.
• The broader industry trends, such as the surge in biotech IPOs and positive clinical results from other companies like Eli Lilly, could have created a favorable environment for Moderna's stock to thrive amidst growing interest in the biopharmaceutical sector.
• Overall, Moderna's strong performance today could be seen as a culmination of positive news flow, market dynamics, and investor expectations aligning in favor of the company's growth prospects.

26.05.2026 - MRNA Stock was up 13.9%

• The positive movement in Moderna's stock is driven by the FDA advisory committee's backing of its flu vaccine, fostering confidence among investors regarding the company's future.
• Robust revenue growth in Q1 further reinforces Moderna's market position and demonstrates its ability to meet its financial targets.
• Despite the significant surge and gains so far this year, analysts on Wall Street are exercising caution, with price targets below current trading levels, hinting at possible concerns of overvaluation.
• Analysts making adjustments to price targets and maintaining "Hold" recommendations reflect varied sentiments in the market, underscoring the importance for investors to evaluate Moderna's valuation and growth potential diligently before making any investment choices.

26.05.2026 - MRNA Stock was up 11.9%

• Moderna's stock surged over 14% today, reaching $68.23, driven by positive developments in its mRNA therapeutic pipeline, particularly the FDA advisory committee's endorsement of its flu vaccine, mFLUSIVA.
• The company's strategic restructuring into three commercial franchises and plans for manufacturing investment in Germany showcased its evolution beyond COVID-19, attracting momentum traders and boosting investor confidence.
• Despite the strong performance, concerns linger around the company's profitability challenges, as indicated by its GF Score™ of 58/100 and notable insider selling activity, warranting caution among Wall Street analysts despite the stock's impressive run.
• Moderna's outperformance compared to other vaccine stocks like Merck and Pfizer today underscores the market's positive reception of its pipeline news and revenue growth, positioning the company as a diversified mRNA platform player with promising prospects.

26.05.2026 - MRNA Stock was up 5.4%

• Moderna is strategically focusing on expanding its pipeline with new therapeutic modalities and commercial products as part of its plan to break even by 2028. This forward-looking strategy has positively influenced investor sentiment and the stock's performance.
• An adjustment of Moderna's price target by analysts at Jefferies indicates confidence in the company's future prospects, especially following a positive FDA panel recommendation regarding its mRNA-based influenza vaccine. This optimism likely contributed to the stock's bullish movement.
• The impending FDA approval of Moderna's mRNA-1010 flu vaccine has been a key driver of the stock's recent gains. Despite doubling in value this year, the company's promising pipeline, which includes a personalized cancer vaccine and an HIV vaccine, continues to attract investors.
• While financial metrics remain important, market interest in Moderna seems to be centered on its innovative capabilities, upcoming catalysts, and strategic growth initiatives, all of which have propelled the stock to new heights.

18.05.2026 - MRNA Stock was up 5.5%

• Moderna's bullish movement today could be attributed to the company considering acquiring BioNTech's German manufacturing plants. This strategic move not only expands Moderna's production capacity but also positions it favorably in the European market.
• Additionally, the FDA clearance for Beam Therapeutics' BEAM-304 PKU gene-editing trial may have indirectly boosted Moderna's stock, as it highlights the advancements in genetic therapies within the biotech sector.
• The FDA scrutiny of Moderna's mRNA flu vaccine could have also impacted the stock positively, as it demonstrates the company's commitment to expanding its vaccine portfolio beyond COVID-19 solutions.
• Overall, Moderna's proactive approach towards acquisitions, clinical trials, and vaccine development seems to have resonated well with investors, driving the bullish movement in its stock price today.

18.05.2026 - MRNA Stock was up 8.0%

• Moderna's bullish movement can be attributed to the positive news surrounding its mRNA flu vaccine facing FDA scrutiny for approval in older adults. This potential approval would mark a significant milestone for the company, especially in the competitive flu vaccine market.
• The anticipation of Moderna entering the flu vaccine market with its mRNA technology, competing with traditional vaccine companies like Sanofi and GSK, has likely sparked investor optimism and contributed to the bullish trend.
• Investors may view Moderna's innovative approach to vaccine development and its potential expansion into new markets as a positive sign for the company's growth prospects, driving the stock price higher.
• The news of Moderna's mRNA flu vaccine progress overshadowed other headlines in the biotechnology sector, keeping the focus on the company's promising developments and future potential.

23.05.2026 - MRNA Stock was up 6.5%

• Following a positive outcome from an FDA advisory committee vote on the benefit-risk profile of their seasonal flu vaccine, mRNA-1010, Moderna's stock witnessed a significant rise. This development has bolstered investor confidence in the company's vaccine portfolio.
• The market's response to Moderna's recent announcement contrasts with another company's stock decline, emphasizing the importance of regulatory approvals and product advancements in shaping stock performance.
• Moderna's stock upsurge mirrors investors' confidence in its growth potential, driven by its mRNA technology and upcoming product launches. It signifies a strong market belief in Moderna's capacity to provide innovative healthcare solutions.

29.05.2026 - MRNA Stock was up 12.6%

• Moderna's stock surged almost 13% to hit a 52-week high as the company revealed its strategies to expand beyond vaccines and venture into broader biotechnology avenues. This move, which includes utilizing its mRNA platform for diverse therapies and incorporating AI for drug discovery, excited investors and led to a rise in the stock price.
• Anticipation surrounding the FDA's upcoming decision regarding Moderna's mRNA flu shot further fueled positive market sentiment. Analysts hurried to revise their price targets as the stock exceeded many of their previous estimates.
• Patton Fund Management Inc. notably increased its position in Moderna, Inc., indicating a growing faith in the company's future prospects and contributing to the stock's bullish trend.
• Market reactions indicate optimism towards Moderna's growth initiatives and the potential applications of its mRNA technology across various therapeutic fields, demonstrating investor trust in the company's long-term trajectory.

29.05.2026 - MRNA Stock was up 12.6%

• Moderna's stock saw a robust surge exceeding 12% today, outpacing the majority of analyst price targets, as investor attention gravitates towards the company's diverse mRNA initiatives aside from COVID-19.
• The pending FDA decision on Moderna's mRNA flu shot, set for August 5th, stands out as a significant catalyst propelling the stock's upward trajectory.
• Despite analysts upholding a prevailing "Reduce" consensus rating, recent favorable developments surrounding Moderna's expanded portfolio encompassing oncology and autoimmune disorders are prompting a reassessment among investors.
• Moderna's strategic pivot towards the advancement of mRNA therapeutics targeting cancer, autoimmune conditions, and integration of AI-driven research initiatives is instilling a sense of optimism and bolstering investor confidence in the company's future growth prospects.

29.05.2026 - MRNA Stock was up 12.6%

• Moderna's stock saw a surge of over 12% today, surpassing most analyst price targets. This increase can be attributed to the growing investor interest in the company's various mRNA programs extending beyond COVID-19 vaccines.
• The impending FDA decision scheduled for August 5th regarding Moderna’s mRNA flu shot is a pivotal point that has prompted investors to reassess the company's stock. This reassessment follows positive updates related to Moderna's pipeline expansion in fields such as oncology and autoimmune diseases.
• The appointment of Srishti Gupta as the new CEO of NovaBridge Biosciences, along with encouraging outcomes from HCA Healthcare's gene-editing therapy study, likely influenced the optimistic mood within the biotech sector, consequently benefiting Moderna.
• Despite the notable uptrend in the stock, there are apprehensions regarding its valuation, with concerns arising about potential overvaluation due to the rapid surge and upcoming regulatory events, urging investors to exercise caution.

22.05.2026 - MRNA Stock was down 5.2%

• Confirmation of Moderna's mRNA flu vaccine, mRNA-1010, passing the FDA Advisory Committee meeting is viewed positively, notwithstanding concerns about weak operational performance and high valuation.
• Leerink Partners' adjustment of the price target and maintenance of an "Underperform" rating are seen as contributing to the prevailing negative sentiment.
• Despite a recent 6-day streak of gains and a significant increase in market capitalization, worries regarding the company's financial health and valuation being deemed "Very Unattractive" may have overshadowed any positive trend.
• The $2.25 billion settlement with Roivant Sciences could have adversely affected Moderna's stock, despite providing legal clarity, as investors might be wary of its implications on Moderna's finances and future prospects.

25.05.2026 - MRNA Stock was down 5.5%

• Today's bearish movement for Moderna could be due to profit-taking by investors following the company's Science Day event, where advancements in its mRNA pipeline were showcased without any major breakthroughs or immediate revenue-generating milestones being announced.
• The market's negative reaction may stem from the absence of near-term commercial growth catalysts, as Moderna highlighted a long-term innovation strategy across multiple therapeutic areas like cancer and autoimmune diseases.
• Investor caution might be influenced by the high expectations set by Moderna in diversifying its pipeline and expanding its mRNA platform. This caution has led to a sell-off as investors await more concrete clinical data and revenue projections.